L. Stephens

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

K. Griffith, A. Jakubowiak, R. Vij, 2020, Blood.

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

A. Jakubowiak, T. Zimmerman, T. Karrison, 2019, British journal of haematology.

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

K. Griffith, A. Jakubowiak, R. Vij, 2016 .

Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma.

S. Jeremiah, T. Bogdanova, E. Demidchik, 2005, Thyroid : official journal of the American Thyroid Association.

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.

K. Griffith, A. Jakubowiak, T. Zimmerman, 2016 .

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

K. Griffith, A. Jakubowiak, R. Vij, 2017 .